These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. HPV E6/E7mRNA association with interleukin 10 (rs1800872) polymorphism in a group of Macedonian women. Duvlis S, Dabeski D, Hiljadnikova-Bajro M, Osmani D, Memeti S. J Med Virol; 2022 Sep; 94(9):4485-4489. PubMed ID: 35578823 [Abstract] [Full Text] [Related]
6. Detection of human papillomavirus E6/E7 mRNA in women with high-risk HPV types 16, 18, 31, 33 and 45 which are associated with the development of human cervical cancer. Bertuccio MP, Spataro P, Caruso C, Picerno I. Eur J Gynaecol Oncol; 2011 Sep; 32(1):62-4. PubMed ID: 21446327 [Abstract] [Full Text] [Related]
7. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia. Persson M, Brismar Wendel S, Ljungblad L, Johansson B, Weiderpass E, Andersson S. Oncol Rep; 2012 Jul; 28(1):346-52. PubMed ID: 22484610 [Abstract] [Full Text] [Related]
8. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, Klimek F, Andersson S, Tommasino M. Cancer Res; 2001 Jan 15; 61(2):608-11. PubMed ID: 11212257 [Abstract] [Full Text] [Related]
11. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women. Duvlis S, Popovska-Jankovic K, Arsova ZS, Memeti S, Popeska Z, Plaseska-Karanfilska D. J Med Virol; 2015 Sep 15; 87(9):1578-86. PubMed ID: 25880030 [Abstract] [Full Text] [Related]
14. Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker. Fontecha N, Basaras M, Hernáez S, Andía D, Cisterna R. BMC Cancer; 2016 Nov 05; 16(1):852. PubMed ID: 27816058 [Abstract] [Full Text] [Related]
15. Prevalence of type-specific oncogenic human papillomavirus infection assessed by HPV E6/E7 mRNA among women with high-grade cervical lesions. Wang HY, Park S, Lee D, Kim S, Kim G, Park KH, Lee H. Int J Infect Dis; 2015 Aug 05; 37():135-42. PubMed ID: 26141414 [Abstract] [Full Text] [Related]
17. Use of hTERT and HPV E6/E7 mRNA RT-qPCR TaqMan assays in combination for diagnosing high-grade cervical lesions and malignant tumors. Wang HY, Park S, Kim S, Lee D, Kim G, Kim Y, Park KH, Lee H. Am J Clin Pathol; 2015 Mar 05; 143(3):344-51. PubMed ID: 25696792 [Abstract] [Full Text] [Related]
19. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China. Wang HY, Lee D, Park S, Kim G, Kim S, Han L, Yubo R, Li Y, Park KH, Lee H. Asian Pac J Cancer Prev; 2015 Mar 05; 16(17):7633-40. PubMed ID: 26625774 [Abstract] [Full Text] [Related]
20. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system. Chen Y, Jiang H, Wang T, He D, Tian R, Cui Z, Tian X, Gao Q, Ma X, Yang J, Wu J, Tan S, Xu H, Tang X, Wang Y, Yu Z, Han H, Das BC, Severinov K, Hitzeroth II, Debata PR, Xu W, Fan W, Jin Z, Cao C, Yu M, Xie W, Huang Z, Hu Z, You Z. Antiviral Res; 2020 Jun 05; 178():104794. PubMed ID: 32298665 [Abstract] [Full Text] [Related] Page: [Next] [New Search]